The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients
The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients
复制标题
血小板内皮细胞粘附分子1对非小细胞肺癌患者预后的价值
DOI：
10.1007/s12032-013-0536-5
复制
发表时间：
2013-06-01
期刊：
影响因子：
3.4
通讯作者：
Zhang, Xing
中科院分区：
文献类型：
--
作者：
Kuang, Bo-hua;Wen, Xi-zhi;Zhang, Xing
我们以前的研究表明，血小板内皮细胞黏附分子-1(PECAM-1)是免疫球蛋白超家族的成员，是肺癌细胞锚定非依赖性生长和抗失巢凋亡的关键介质。本研究旨在探讨PECAM-1在非小细胞肺癌(NSCLC)组织中的表达及其临床意义。免疫组织化学显示PECAM-1在NSCLC间质组织中呈高微血管密度。PECAM1的微血管密度与非小细胞肺癌患者的N分期(p=0.029)、M分期(p=0.001)和临床分期(p=0.001)密切相关。生存分析显示PECAM-1在非小细胞肺癌原发灶和转移性淋巴结组织中的微血管密度都很高，并且这些结果与非小细胞肺癌患者总体生存不良显著相关(p<；分别为0.001和p=0.021)。此外，在腺癌或EGFR突变亚组中，PECAM-1微血管密度高的患者总体生存率较差。多因素分析显示，PECAM-1的微血管密度是影响NSCLC患者预后的独立因素。PECAM-1的微血管密度也是接受一线铂类双重化疗的非小细胞肺癌患者的潜在预测指标，因为高的PECAM-1微血管密度与较差的总体生存相关。我们的结果表明，PECAM-1的微血管密度可能是NSCLC一个潜在的预后因素和治疗靶点。
Our previous studies have shown that platelet endothelial cell adhesion molecule-1 (PECAM-1), a member of the immunoglobulin superfamily, is a critical mediator of anchorage-independent growth and anoikis resistance in lung carcinoma cells. The purpose of this study was to analyze the protein expression of PECAM-1 in non-small-cell lung carcinoma (NSCLC) tissues and its clinical significance in NSCLC patients. By immunohistochemical analysis, high microvessel density (MVD) of PECAM-1 was detected in the stromal tissues of NSCLC. The MVD of PECAM-1 was strongly correlated with the N stage (p= 0.029), M stage (p= 0.001) and clinical stage (p= 0.001) of NSCLC patients. Survival analysis revealed high MVD of PECAM-1 in both primary NSCLC lesions and metastatic lymph node tissues, and these results were found to be significantly correlated with poor overall survival in NSCLC patients (p< 0.001 andp= 0.021, respectively). Moreover, patients with high PECAM-1 MVD had worse overall survival in either adenocarcinoma or EGFR mutation subgroups. Multivariate analysis revealed that the MVD of PECAM-1 was an independent prognostic factor for NSCLC patients. The MVD of PECAM-1 is also a potential predictor for NSCLC patients treated with first-line platinum-based doublet chemotherapy, as high PECAM-1 MVD correlated with worse overall survival. Our results demonstrated that MVD of PECAM-1 could be a potential prognostic factor and therapeutic target in NSCLC.